Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 17, Art. 3 (pp. 24-45)    |    2016       

»

Effectiveness and safety of using a succinate-based dietary supplement for women in menopause

1 Kuznetsova I.V., 1 Uspenskaya Y.B., 2 Borisova N.I., 2 Zhukova E.V., 3 Berdnikova N.G., 4 Gusak Y.K.

I.M. Sechenov First Moscow State Medical University: women's health research center 1,
university hospital N2 2,
department of clinical pharmacology and propedeutics of internal diseases 3;
I.P. Pavlov Ryzan State Medical University, department of obstetrics and gynecology 4

Brief summary

Objective of this study was to evaluate the effectiveness and safety of using a succinate-based dietary supplement complex (SBDSC) to relieve vasomotor and psychosomatic symptoms in perimenopausal and postmenopausal women. Methods. Randomized, double-blind, placebo-controlled trial was conducted among women 42?60 years of age with vasomotor and psychosomatic menopausal symptoms. The study included medical evaluations, questionnaires using the Greene Climacteric Scale and the Spielberger-Hanin test, evaluation of plasma levels of gonadotropins, estradiol, leptin, and apolipoproteins. Results. The study included 104 women, randomized to two groups. Analysis of the Greene Climacteric Scale results showed a statistically significant (р<0.05) improvement in 13 out of 21 menopausal symptoms in patients who took SBDSC. During the course of the SBDSC treatment and by the end of the study the patients showed significant changes in the levels of estradiol and gonadotropins, decrease in the average body weight and waist circumference. The Spielberger-Hanin test showed that SBDSC supplementation allows for stabilization of patients? psychological status with significant reduction in anxiety, increased resistance to stress, and improved adaptability. Comparative analysis of vital signs, blood and urine tests did not show any negative effects of SBDSC. Conclusion: using SBDSC during menopause and postmenopause can be considered a method to relieve vasomotor and psychosomatic menopausal symptoms for women who have counter indications for HRT or do not wish to undergo HRT.


Key words

menopause, vasomotor and psychosomatic menopausal symptoms, mitochondrial dysfunction, treatment of menopausal symptoms, ammonium succinate.

Reference list

1. Whiteley J, DiBonaventura M, Wagner JS, Alvir J, Shah S. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J Womens Health (Larchmt). 2013;22:983-90.


2. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310:1353-68.


3. Wieder-Huszla S, Szkup M, Jurczak A, Samochowiec A, Samochowiec J, Stanislawska M, Rotter I, Karakiewicz B, Grochans E. Effects of socio-demographic, personality and medical factors on quality of life of postmenopausal women. Int J Environ Res Public Health. 2014;11:6692-708.


4. Genazzani AR, Gambacciani M, Simoncini T. Menopause and aging, quality of life and sexuality. Climacteric. 2007;10:88-96.


5. Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Granger AL, Fehnel SE, Levine KB, Jordan J, Clark RV. Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric. 2008;11:32-43.


6. Rapkin AJ. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol. 2007;196:97-106.


7. Freedman RR, Benton MD, Genik RJ, 2nd, Graydon FX. Cortical activation during menopausal hot flashes. Fertil Steril. 2006;85:674-8.


8. Henderson VW. Aging, estrogens, and episodic memory in women. Cogn Behav Neurol. 2009;22:205-14.


9. Schmidt P. The 2012 hormone therapy position statement of the North American Menopause Society. Menopause (New York, NY). 2012;19:257.


10. Sturdee D, Pines A. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011;14:302-20.


11. De Villiers T, Pines A, Panay N, Gambacciani M, Archer D, Baber R, Davis S, Gompel A, Henderson V, Langer R. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013;16:316-37.


12. Sood R, Faubion SS, Kuhle CL, Thielen JM, Shuster LT. Prescribing menopausal hormone therapy. International journal of women's health. 2014;6:47-57.


13. Gompel A, Rozenberg S, Barlow DH, members Eb. The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas. 2008;61:227-32.


14. Hill DA, Hill SR. Counseling patients about hormone therapy and alternatives for menopausal symptoms. Am Fam Physician. 2010;82:801-7.


15. Cho GJ, Lee JH, Park HT, Shin JH, Hong SC, Kim T, Hur JY, Lee KW, Park YK, Kim SH. Postmenopausal status according to years since menopause as an independent risk factor for the metabolic syndrome. Menopause. 2008;15:524-9.


16. Jeanes H, Newby D, Gray GA. Cardiovascular risk in women: the impact of hormone replacement therapy and prospects for new therapeutic approaches. Expert Opin Pharmacother. 2007;8:279-88.


17. Lundholm L, Zang H, Hirschberg AL, Gustafsson JA, Arner P, Dahlman-Wright K. Key lipogenic gene expression can be decreased by estrogen in human adipose tissue. Fertil Steril. 2008;90:44-8.


18. Alonso A, Gonzalez-Pardo H, Garrido P, Conejo NM, Llaneza P, Diaz F, Del Rey CG, Gonzalez C. Acute effects of 17 beta-estradiol and genistein on insulin sensitivity and spatial memory in aged ovariectomized female rats. Age (Dordr). 2010;32:421-34.


19. Geer EB, Shen W. Gender differences in insulin resistance, body composition, and energy balance. Gend Med. 2009;6 Suppl 1:60-75.


20. Monteiro R, Teixeira D, Calhau C. Estrogen signaling in metabolic inflammation. Mediators Inflamm. 2014;2014:615917.


21. Oseni T, Patel R, Pyle J, Jordan VC. Selective estrogen receptor modulators and phytoestrogens. Planta Med. 2008;74:1656-65.


22. Speroff L, Gass M, Constantine G, Olivier S, Study I. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2008;111:77-87.


23. Loprinzi CL, Qin R, Baclueva EP, Flynn KA, Rowland KM, Graham DL, Erwin NK, Dakhil SR, Jurgens DJ, Burger KN. Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes, N07C1. Journal of Clinical Oncology. 2010;28:641-7.


24. Evans M, Elliott JG, Sharma P, Berman R, Guthrie N. The effect of synthetic genistein on menopause symptom management in healthy postmenopausal women: a multi-center, randomized, placebo-controlled study. Maturitas. 2011;68:189-96.


25. Chen TT, Maevsky EI, Uchitel ML. Maintenance of homeostasis in the aging hypothalamus: the central and peripheral roles of succinate. Front Endocrinol (Lausanne). 2015;6:7.


26. Sydakov N, Nikiforov S, Konstantinov U, Klimenkov I, Novikova M, Lepehova S. Rol perekisno-modificirovannih lipoproteidov v mehanizmah razvitiya mitohondrialnoi disfynkcii sosydov pri ateroskleroze. Bulleten Vostochno-Sibirskogo naychnogo centra Sibirskogo otdeleniya Rossiiskoi akademii medicinskih nayk. 2008.


27. Ahmetov I, Popov D, Missina S, Vinogradova O, Rogozkin V. Association of mitochondrial transcription factor (TFAM) gene polymorphism with physical performance in athletes. Human physiology. 2010;36:229-33.


28. Jeikova TV, Golybenko M, Byikin S, Makeeva O, Lejnev A, Cimbaluk I, Shipylin V, Pyzir?v V. Associaciya polimorfizma Thr12Ser gena mitohondrialnogo faktora transkripcii A TFAM s ishemicheskoi boleznu serdca. Bulleten sibirskoi medicini. 2012;11.


29. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194-217.


30. Maevsky EI, Peskov AB, Uchitel ML, Pogorelov AG, Saharova NY, Vihlyantseva EF, Bogdanova LA, Kondrashova MN. A succinate-based composition reverses menopausal symptoms without sex hormone replacement therapy. Adv Gerontol. 2008;21:298-305.


31. Kuznetsova I.V. UYB, Borisova N.I., Zhukova E.V., Berdnikova N.G., Gusak Yu.K. Akusherstvo i ginekologiya/Obstetrics and Gynecology. . Efficiency of alternative therapy in perimenopausal and postmenopausal women (in Russian). Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2016 5:126 - 33.


32. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ. Executive summary of the Stages of Reproductive Aging Workshop+ 10: addressing the unfinished agenda of staging reproductive aging. Climacteric. 2012;15:105-14.


33. Greene J. Guide to the Greene climacteric scale. Glasgow: University of Glasgow. 1991.


34. Greene JG. Constructing a standard climacteric scale. Maturitas. 1998;29:25-31.


35. Freedman RR, Roehrs TA. Sleep disturbance in menopause. Menopause. 2007;14:826-9.


36. Ziv-Gal A, Flaws JA. Factors that may influence the experience of hot flushes by healthy middle-aged women. Journal of Women's Health. 2010;19:1905-14.


37. Loprinzi CL, Barton DL. On hot flash mechanism, measurement, and treatment. Menopause. 2009;16:621-3.


38. Freedman RR. Menopausal hot flashes: mechanisms, endocrinology, treatment. The Journal of steroid biochemistry and molecular biology. 2014;142:115-20.


39. Schilling C, Gallicchio L, Miller SR, Langenberg P, Zacur H, Flaws JA. Genetic polymorphisms, hormone levels, and hot flashes in midlife women. Maturitas. 2007;57:120-31.


40. Sinchak K, Wagner EJ. Estradiol signaling in the regulation of reproduction and energy balance. Frontiers in neuroendocrinology. 2012;33:342-63.


41. Sowers MR, Zheng H, Greendale GA, Neer RM, Cauley JA, Ellis J, Johnson S, Finkelstein JS. Changes in bone resorption across the menopause transition: effects of reproductive hormones, body size, and ethnicity. J Clin Endocrinol Metab. 2013;98:2854-63.


42. Skurnick JH, Weiss G, Goldsmith LT, Santoro N, Crawford S. Longitudinal changes in hypothalamic and ovarian function in perimenopausal women with anovulatory cycles: relationship with vasomotor symptoms. Fertility and sterility. 2009;91:1127-34.


43. Toffoletto S, Lanzenberger R, Gingnell M, Sundström-Poromaa I, Comasco E. Emotional and cognitive functional imaging of estrogen and progesterone effects in the female human brain: A systematic review. Psychoneuroendocrinology. 2014;50:28-52.


44. Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiological reviews. 2008;88:611-38.


45. Zhang L, Chan SS, Wolff DJ. Mitochondrial disorders of DNA polymerase gamma dysfunction: from anatomic to molecular pathology diagnosis. Arch Pathol Lab Med. 2011;135:925-34.


46. Long J, He P, Shen Y, Li R. New evidence of mitochondria dysfunction in the female Alzheimer's disease brain: deficiency of estrogen receptor-β. Journal of Alzheimer's Disease. 2012;30:545-58.


47. Markham A, Bains R, Franklin P, Spedding M. Changes in mitochondrial function are pivotal in neurodegenerative and psychiatric disorders: how important is BDNF? British journal of pharmacology. 2014;171:2206-29.


48. Velarde MC. Pleiotropic actions of estrogen: a mitochondrial matter. Physiological genomics. 2013;45:106-9.


49. Sowers M, Zheng H, Tomey K, Karvonen-Gutierrez C, Jannausch M, Li X, Yosef M, Symons J. Changes in body composition in women over six years at midlife: ovarian and chronological aging. The Journal of Clinical Endocrinology & Metabolism. 2007;92:895-901.


50. Soni AC, Conroy MB, Mackey RH, Kuller LH. Ghrelin, leptin, adiponectin, and insulin levels and concurrent and future weight change in overweight postmenopausal women. Menopause (New York, NY). 2011;18:296.


51. Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després J-P, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MRG. The cardiometabolic health alliance: working toward a new care model for the metabolic syndrome. Journal of the American College of Cardiology. 2015;66:1050-67.


52. Nathan DM. Diabetes: Advances in Diagnosis and Treatment. JAMA. 2015;314:1052-62.


53. Allott EH, Hursting SD. Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer. 2015;22:R365-86.


54. Osellame LD, Blacker TS, Duchen MR. Cellular and molecular mechanisms of mitochondrial function. Best Practice & Research Clinical Endocrinology & Metabolism. 2012;26:711-23.


55. Fischer-Posovszky P, Wabitsch M, Hochberg Z. Endocrinology of adipose tissue-an update. Hormone and metabolic research= Hormon-und Stoffwechselforschung= Hormones et metabolisme. 2007;39:314-21.


56. Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim SY, Hamnvik OP, Koniaris A. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab. 2011;301:E567-84.


57. Yau SW, Henry BA, Russo VC, McConell GK, Clarke IJ, Werther GA, Sabin MA. Leptin enhances insulin sensitivity by direct and sympathetic nervous system regulation of muscle IGFBP-2 expression: evidence from nonrodent models. Endocrinology. 2014;155:2133-43.


58. Hausman GJ, Barb CR, Lents CA. Leptin and reproductive function. Biochimie. 2012;94:2075-81.


59. Donato J, Jr., Cravo RM, Frazao R, Elias CF. Hypothalamic sites of leptin action linking metabolism and reproduction. Neuroendocrinology. 2011;93:9-18.